Literature DB >> 23255924

Expression of β-adrenergic receptors in pediatric malignant brain tumors.

Iacopo Sardi1, Laura Giunti, Cecilia Bresci, Anna Maria Buccoliero, Duccio Degl'innocenti, Stefania Cardellicchio, Gianna Baroni, Francesca Castiglione, Martina DA Ros, Patrizio Fiorini, Sabrina Giglio, Lorenzo Genitori, Maurizio Aricò, Luca Filippi.   

Abstract

β-adrenergic receptors (β-ARs) are G protein-coupled receptors that activate signal transduction pathways involved in angiogenesis, resulting in enhanced tumor vascularization and more aggressive growth. In this study, we evaluated the expression of β-ARs in a population of 12 children affected by malignant primary brain tumors. We found a significant expression of β1- and β2-ARs in all 12 samples as well as the 3 cell lines tested (U87MG, T98G and DAOY). The mean absolute β1-AR mRNA level standardized to GAPDH was 5.81 (range, -7.91 to 11.29) for brain tumors and 8.59 (range, 6.046 to 12.59) for cell lines (U87MG, DAOY and T98G), respectively. The mean absolute β2-AR mRNA level was 4.74 (range, -9.30 to 8.45) for tumor specimens and 7.64 (range, 5.85 to 8.88) for cell lines. These real-time quantitative (qRT)-PCR expression data were confirmed by immunohistochemical analysis. Our study evaluated the presence of β1- and β2-ARs in malignant pediatric brain tumors and brain tumor cell lines.

Entities:  

Year:  2012        PMID: 23255924      PMCID: PMC3525361          DOI: 10.3892/ol.2012.989

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.

Authors:  Stanley Lemeshow; Henrik Toft Sørensen; Gary Phillips; Eric V Yang; Sussie Antonsen; Anders H Riis; Gregory B Lesinski; Rebecca Jackson; Ronald Glaser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-20       Impact factor: 4.254

3.  Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.

Authors:  Amal Melhem-Bertrandt; Mariana Chavez-Macgregor; Xiudong Lei; Erika N Brown; Richard T Lee; Funda Meric-Bernstam; Anil K Sood; Suzanne D Conzen; Gabriel N Hortobagyi; Ana-Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

4.  Antihypertensive drug use and the risk of prostate cancer (Canada).

Authors:  Linda Perron; Isabelle Bairati; François Harel; François Meyer
Journal:  Cancer Causes Control       Date:  2004-08       Impact factor: 2.506

5.  {Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells.

Authors:  L Toll; L Jimenez; N Waleh; K Jozwiak; A Y-H Woo; R-P Xiao; M Bernier; I W Wainer
Journal:  J Pharmacol Exp Ther       Date:  2010-11-11       Impact factor: 4.030

6.  Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.

Authors:  Chiara Ristori; Luca Filippi; Massimo Dal Monte; Davide Martini; Maurizio Cammalleri; Pina Fortunato; Giancarlo la Marca; Patrizio Fiorini; Paola Bagnoli
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

7.  Expression of beta 2-adrenoceptors mediating cyclic AMP accumulation in astroglial and neuronal cell lines derived from the rat CNS.

Authors:  A Ruck; P Millns; D A Kendall; S J Hill
Journal:  Biochem Pharmacol       Date:  1990-11-15       Impact factor: 5.858

8.  The sympathetic nervous system induces a metastatic switch in primary breast cancer.

Authors:  Erica K Sloan; Saul J Priceman; Benjamin F Cox; Stephanie Yu; Matthew A Pimentel; Veera Tangkanangnukul; Jesusa M G Arevalo; Kouki Morizono; Breanne D W Karanikolas; Lily Wu; Anil K Sood; Steven W Cole
Journal:  Cancer Res       Date:  2010-09-07       Impact factor: 12.701

Review 9.  Catecholamines regulate tumor angiogenesis.

Authors:  Debanjan Chakroborty; Chandrani Sarkar; Biswarup Basu; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

Review 10.  Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters.

Authors:  Frank Entschladen; Theodore L Drell; Kerstin Lang; Jan Joseph; Kurt S Zaenker
Journal:  Lancet Oncol       Date:  2004-04       Impact factor: 41.316

View more
  8 in total

1.  Concurrent activation of β2-adrenergic receptor and blockage of GPR55 disrupts pro-oncogenic signaling in glioma cells.

Authors:  Artur Wnorowski; Justyna Such; Rajib K Paul; Robert P Wersto; Fred E Indig; Krzysztof Jozwiak; Michel Bernier; Irving W Wainer
Journal:  Cell Signal       Date:  2017-05-08       Impact factor: 4.315

Review 2.  Stress, metabolism and cancer: integrated pathways contributing to immune suppression.

Authors:  Elizabeth A Repasky; Jason Eng; Bonnie L Hylander
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

3.  The interplay among psychological distress, the immune system, and brain tumor patient outcomes.

Authors:  Sebastian Otto-Meyer; Jan Lumibao; Eugene Kim; Erik Ladomersky; Lijie Zhai; Kristen L Lauing; Denise M Scholtens; Frank Penedo; Christina Amidei; Rimas V Lukas; Derek A Wainwright
Journal:  Curr Opin Behav Sci       Date:  2019-02-26

4.  Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma.

Authors:  Jing-Jing He; Wen-Hua Zhang; Shi-Ling Liu; Yi-Fang Chen; Chen-Xi Liao; Qian-Qing Shen; Ping Hu
Journal:  Oncol Lett       Date:  2017-07-21       Impact factor: 2.967

Review 5.  A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response.

Authors:  Jason W-L Eng; Kathleen M Kokolus; Chelsey B Reed; Bonnie L Hylander; Wen W Ma; Elizabeth A Repasky
Journal:  Cancer Immunol Immunother       Date:  2014-10-12       Impact factor: 6.968

6.  Antitumor activity of (R,R')-4-methoxy-1-naphthylfenoterol in a rat C6 glioma xenograft model in the mouse.

Authors:  Michel Bernier; Rajib K Paul; Katina S S Dossou; Artur Wnorowski; Anuradha Ramamoorthy; Arnaud Paris; Ruin Moaddel; Jean-François Cloix; Irving W Wainer
Journal:  Pharmacol Res Perspect       Date:  2013-12-05

Review 7.  Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response.

Authors:  Guanxi Qiao; Minhui Chen; Mark J Bucsek; Elizabeth A Repasky; Bonnie L Hylander
Journal:  Front Immunol       Date:  2018-02-06       Impact factor: 7.561

Review 8.  β adrenergic receptor modulated signaling in glioma models: promoting β adrenergic receptor-β arrestin scaffold-mediated activation of extracellular-regulated kinase 1/2 may prove to be a panacea in the treatment of intracranial and spinal malignancy and extra-neuraxial carcinoma.

Authors:  George Zaki Ghali; Michael George Zaki Ghali
Journal:  Mol Biol Rep       Date:  2020-04-18       Impact factor: 2.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.